drugset / Trial / NCT04574024

HFS (High-Fiber Supplement) in MS (Multiple Sclerosis)

NCT04574024 ↗

Phase 1/2 Completed 7 enrolled Suhayl Dhib-Jalbut, MD
NaSequentialOpen-labelBasic science

Summary

Multiple sclerosis (MS) is an autoimmune disease directed against the Central Nervous System (CNS). Recent studies have indicated that changes in the gut microbiota are associated with disease initiation and progression. The reduction of bacterial taxa involved in producing health-promoting metabolites, such as short-chain fatty acids (SCFAs), has been reported in MS patients. SCFAs play an important role in the suppression of inflammation. The levels of SCFAs in the blood of MS patients are significantly reduced when compared to those of healthy controls. Since the intake of dietary fiber increases the growth of SCFA-producing bacteria, we investigated the effect of a high-fiber supplement (HFS) on gut bacteria and immunological parameters in MS patients.

Timeline

Start
2022-03-21
Primary completion
2024-06-30
Completion
2024-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject NBT-NM108 Other / unclassified 60 g —

Indications